<DOC>
	<DOCNO>NCT01046422</DOCNO>
	<brief_summary>The purpose study determine BMS-770767 safe , well tolerate , measure level blood ( pharmacokinetics ) , measure level chemical ( biomarkers ) may affect drug ( pharmacodynamics ) type 2 diabetes patient population</brief_summary>
	<brief_title>Safety Study BMS-770767 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosed type 2 diabetes inadequate glycemic control treat either diet exercise alone , stable dos ( ≥ 1500mg/d ) metformin least 8 week prior screen HbA1c ≥ 7.0 % ≤ 10.0 % FPG ≤ 240mg/dL ( 13.3 mmol/dL ) Women childbearing potential History diabetic ketoacidosis hyperosmolar nonketotic coma Significant cardiovascular history History unstable rapidly progress renal disease Impaired renal function define serum creatinine &gt; 1.4mg/dL ( 124 µmol/L ) woman &gt; 1.5mg/dL ( 133 µmol/L ) men Active liver disease /or significant abnormal liver function define AST &gt; 3X ULN and/or ALT &gt; 3XULN /or serum total bilirubin &gt; 2.0mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>